SURMOUNT-3: tirzepatide after intensive lifestyle change

After the lead-in, the tirzepatide group went on to lose a large additional percentage of body weight, while the placebo group generally regained weight over the same window. Combined with the lead-in loss, total reductions in the tirzepatide arm were among the largest in the program.

The placebo group's regain after a strong lifestyle start mirrors a broader finding across obesity research: without ongoing intervention, the body tends to defend a higher weight. This sets up the SURMOUNT-4 question of what happens when the drug itself is stopped.

SURMOUNT-3's design — requiring meaningful weight loss before randomization — is unusual and informative. By enrolling only people who had already demonstrated they could lose weight with intensive lifestyle change, the trial isolated the question of what the drug adds to a motivated, already-succeeding population. The finding that the placebo group regained while the tirzepatide group lost more suggests that early lifestyle success, on its own, is hard to sustain against the body's defenses — and that the medication helps hold and extend those gains. It also means the results may not generalize identically to people who have not done a lifestyle lead-in. For readers, the takeaway is not that lifestyle change is futile (the lead-in produced real loss) but that medication and behavior change are complementary tools, each addressing part of a stubborn biological problem. This reinforces why durable programs pair the drug with ongoing support rather than treating either as sufficient alone.